Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
about
Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegalyAdvancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease ParadigmsRecent advances in the management of acromegalyPasireotide: a novel treatment for patients with acromegalyCurrent therapies and mortality in acromegalyInterpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyHyperglycemia induced by pasireotide in patients with Cushing's disease or acromegalyTargeting kinase signaling pathways with constrained peptide scaffolds.Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.Pegvisomant in acromegaly: an update.STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.Medical management of functioning pituitary adenoma: an update.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.Pituitary Medicine From Discovery to Patient-Focused Outcomes.Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) studyFGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumorsUpdate on prognostic factors in acromegaly: Is a risk score possible?Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.Treatment of acromegaly in the era of personalized and predictive medicine.A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.Pasireotide in Acromegaly: A Review.Adverse events associated with somatostatin analogs in acromegaly.Longitudinal evaluation of the natural history of conservatively managed nonfunctioning pituitary adenomas.New therapeutic agents for acromegaly.Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.Pasireotide for the treatment of acromegaly.Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.Current and future medical treatments for patients with acromegaly.Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.The role of combination medical therapy in the treatment of acromegaly.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.Endocrine Hypertension: A Practical Approach.Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.Somatostatin receptor ligands in the treatment of acromegaly.
P2860
Q26741026-FE04B3CE-8490-4CC8-A61C-5A9084D0115FQ26741707-DC1F7C7A-BD50-4454-B51E-824BE949B6BDQ26766199-B364266A-39EC-4E41-BD52-FADB3A0C0378Q26774437-79355465-C58E-40A2-979C-719A9DD4E5E3Q26776238-13F33D46-3155-4CE6-8BCB-E090F70524D8Q26777682-DE455FCD-0159-4A3C-A101-96D36D670254Q26796357-E7FC78F2-B759-4DEE-A650-A11C2947DF09Q28069603-7446C224-D84C-4D18-A6E0-346823D17D4AQ30398451-EE2BBE26-977D-4DB1-8E0E-EE58DFDA235AQ31027960-EC4D084C-5C6B-4BDB-9629-F78F7DA4A847Q31144045-7C541FC5-7B42-4047-8EF0-D7A931BCAB6CQ33725999-C41525AE-8F71-49EA-B8F9-4091EDCC636DQ35408637-EA580A86-ABF2-46C4-9936-0D5AFA37D38CQ35582894-6DD6130B-7732-4DCC-B772-D733A6C7936CQ35943493-2F333F47-7BD1-4F5F-A762-BD7517BE4845Q35977997-010FABBF-11B5-44EE-A14B-64FBC734760AQ36276686-0DC8ABB8-8259-473D-BA43-AE24CE84CBFDQ36716025-48D95939-0470-4277-AEB9-2C62F38657CAQ36911589-FBB2F621-CD46-46FB-A032-A739F2C82259Q36990184-8356AEE2-1848-4C88-97E5-F28965B4878AQ37578420-33CE20C8-8911-4E29-BA55-13CE5FDCFABDQ37709494-BC046F77-E4D8-42D9-B382-E0662CC772ACQ38214473-7F207304-D2F9-484D-99B2-62F23159EA8DQ38233686-E1C13D0A-9B97-44B4-BC31-64125D0C96A6Q38340014-BAB61E98-EE6E-4744-9222-F574724ED3FBQ38373377-D47CE05C-6A2D-44BB-B2AE-10C16D800E90Q38504642-DC696EF6-14FF-49D4-8156-1D77A4A79E54Q38548973-BB54B014-9488-4E73-B176-7350F1C36D90Q38570064-5907E242-EFDF-4B6A-BCD5-85C1E095FF97Q38648739-4ECE6D59-EF3A-4426-9663-6C306DE11D17Q38683309-CD04C58D-2B36-4518-8ECD-8DC803680B0EQ38710873-7434EEDF-9784-48DA-B4CE-C5B5A25815BEQ38779460-7E6FE848-CA17-45DB-A148-8A28F24B7773Q38847622-635F9E16-11C2-41BE-B75B-88203C14D975Q38912799-3D0EFBC5-58C4-48F7-B527-93EA62D78879Q38927318-67D39A4C-E8FA-49C6-B99E-4DA42D039F9DQ38990078-CFCEA9A1-C368-4CC2-A31F-5F81FB9ED609Q39013828-DEE570F4-A8E7-4B22-B88B-CFC1092FF2D1Q39064562-63365538-34C3-4E66-B9B9-9CD7A7B420D4Q39125449-4019BE3D-E071-4A62-B0AE-4767F8DD89B0
P2860
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@en
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@nl
type
label
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@en
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@nl
prefLabel
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@en
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@nl
P2093
P2860
P356
P1476
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
@en
P2093
A J Farrall
A J van der Lely
K Hermosillo Reséndiz
M D Bronstein
M Fleseriu
M Sheppard
P2860
P304
P356
10.1210/JC.2013-2480
P407
P577
2014-01-13T00:00:00Z